Buscar
Mirum Pharmaceuticals Inc
MIRMAñadir a la lista de seguimiento
105.950USD
-6.640-5.90%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
5.50BCap. mercado
PérdidaP/E TTM
Más Datos de Mirum Pharmaceuticals Inc Compañía
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Información de Mirum Pharmaceuticals Inc
Símbolo de cotizaciónMIRM
Nombre de la empresaMirum Pharmaceuticals Inc
Fecha de salida a bolsaJul 18, 2019
Director ejecutivoPeetz (Christopher)
Número de empleados322
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 18
Dirección989 East Hillsdale Boulevard, Suite 300
CiudadFOSTER CITY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94404
Teléfono16506674085
Sitio Webhttps://mirumpharma.com/
Símbolo de cotizaciónMIRM
Fecha de salida a bolsaJul 18, 2019
Director ejecutivoPeetz (Christopher)
Ejecutivos de Mirum Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Christopher (Chris) Peetz
Mr. Christopher (Chris) Peetz
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
389.76K
--
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Independent Chairman of the Board
Independent Chairman of the Board
280.16K
--
Mr. Peter Radovich
Mr. Peter Radovich
President, Chief Operating Officer
President, Chief Operating Officer
52.37K
+32.44%
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Chief Financial Officer
Chief Financial Officer
42.13K
-11.87%
Dr. Joanne Quan, M.D.
Dr. Joanne Quan, M.D.
Chief Medical Officer
Chief Medical Officer
28.65K
+55.50%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.70K
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Director
Independent Director
5.70K
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
Independent Director
Independent Director
--
--
Dr. Pamela Vig, Ph.D.
Dr. Pamela Vig, Ph.D.
Chief Scientific Officer, Head of Research
Chief Scientific Officer, Head of Research
--
--
Ms. Lara Longpre
Ms. Lara Longpre
Chief Development Officer
Chief Development Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Christopher (Chris) Peetz
Mr. Christopher (Chris) Peetz
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
389.76K
--
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Independent Chairman of the Board
Independent Chairman of the Board
280.16K
--
Mr. Peter Radovich
Mr. Peter Radovich
President, Chief Operating Officer
President, Chief Operating Officer
52.37K
+32.44%
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Chief Financial Officer
Chief Financial Officer
42.13K
-11.87%
Dr. Joanne Quan, M.D.
Dr. Joanne Quan, M.D.
Chief Medical Officer
Chief Medical Officer
28.65K
+55.50%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.70K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Mirum Pharmaceuticals Inc?
Los cinco principales accionistas de Mirum Pharmaceuticals Inc son: Mr. Christopher (Chris) Peetz
¿Cuántas instituciones poseen acciones de Mirum Pharmaceuticals Inc (MIRM)?
A fecha de 2026Q1, 541 instituciones poseen acciones de Mirum Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 68.01M, lo que representa el 111.53% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 4804206.00.
¿Cuál es la mayor fuente de ganancias de Mirum Pharmaceuticals Inc?
El 2026Q1, el segmento empresarial Livmarli generó la ganancia más alta para Mirum Pharmaceuticals Inc, ascendiendo a 360.01M y representando el 69.06% de la ganancia total.